Clinical trial · Interventional
Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP)
Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP) in mCRC Patients Treated With First-line Bevacizumab
NCT02511756CI-TRIAL-00025204AVA-CTPterminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Slow accrual
Summary
Brief summary (as posted)
The primary objective of this study is to investigate the anti-angiogenic effect of bevacizumab measured by CTP as a predictive marker for efficacy measured by progression-free survival (PFS) in mCRC patients under first-line bevacizumab-containing, fluoropyrimidine-based chemotherapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Computed tomography X-ray system | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Perfusion-computed tomography (CTP)
- description
- Patients undergo a total of four perfusion-computed tomographies from baseline to progression of disease.
- interventionNames
- Device: Computed tomography X-ray system
Primary outcomes (1)
- measure
- CTP as predictive marker for efficacy measured by progression-free survival
- timeFrame
- one year
- description
- Predictive power of decrease in tumor vasculature on the clinical outcome in bevacizumab-based chemotherapy measured by progression-free survival (PFS). Decrease in tumor vasculature is measured by blood flow in CTP 3 compared to CTP 1 (baseline)
Secondary outcomes (5)
- measure
- CTP as predictive marker for efficacy measured by progression-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years, male or female * Signed written informed consent * Patients with histologically confirmed diagnosis of colorectal cancer with hepatic metastases who are candidates for systemic treatment. * Confirmation of metastatic liver disease within one month prior to inclusion in one of the following radiological procedures: * Contrast-enhanced spiral computed tomography showing at least one liver nodule ≥ 20 mm in longest diameter according to RECIST 1.1 criteria * MR imaging of the liver with liver lesions suspicious for metastases * PET computed tomography (PET/CT) with liver lesions suspicious for metastases * Patient is eligible and designated for treatment with standard-of-care first-line bevacizumab-containing, fluoropyrimidine-based chemotherapy. * ECOG performance status ≤ 2 (see appendix) Exclusion Criteria: * Inability or unwillingness to comply with the participation requirements * History of untreated hyperthyreosis * History of intolerance of or allergy to iodine contrast media according to CTCAE V4.03 * Calculated creatinine clearance \< 45 ml/min * For fertile women: positive urine pregnancy test or lactation. * Known or suspected non-compliance, drug or alcohol abuse * Life expectancy of less than 3 months * Participation in another interventional trial with an investigational medicinal product (IMP) and within 30 days prior to screening
References
Publications (0)
Data not yet available
No reference posted for this study.